T
Thomas L. Holland
Researcher at Duke University
Publications - 74
Citations - 5580
Thomas L. Holland is an academic researcher from Duke University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 57 publications receiving 3660 citations. Previous affiliations of Thomas L. Holland include Intermountain Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
TL;DR: This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of S. aureus as a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections.
Journal ArticleDOI
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.
Nicholas A Turner,Batu K. Sharma-Kuinkel,Stacey A. Maskarinec,Emily M. Eichenberger,Pratik Shah,Manuela Carugati,Manuela Carugati,Thomas L. Holland,Vance G. Fowler,Vance G. Fowler +9 more
TL;DR: An overview of basic and clinical MRSA research is provided and the expansive body of literature on the epidemiology, transmission, genetic diversity, evolution, surveillance and treatment of MRSA is explored.
Journal ArticleDOI
Clinical management of Staphylococcus aureus bacteremia: a review.
TL;DR: In this article, the authors reviewed evidence of management strategies for Staphylococcus aureus bacteremia to determine whether transesophageal echocardiography is necessary in all adult cases and what is the optimal antibiotic therapy for methicillin-resistant S auresus (MRSA) bacterers.
Journal ArticleDOI
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
J D Lundgren,Birgit Grund,Christina E. Barkauskas,Thomas L. Holland,Robert L. Gottlieb,Uriel Sandkovsky,Samuel M. Brown,Kirk U. Knowlton,Wesley H. Self,D. Clark Files,Mamta K Jain,T. Benfield,Michael E Bowdish,Bradley G Leshnower,Jason V. Baker,Jens-Ulrik Stæhr Jensen,Edward M. Gardner,Adit A. Ginde,Estelle S. Harris,Isik Somuncu Johansen,Norman Markowitz,Michael A. Matthay,Lars Østergaard,Christina C. Chang,Victoria J. Davey,Anna L. Goodman,Elizabeth S. Higgs,Elizabeth S. Higgs,Daniel D Murray,Thomas A. Murray,Roger Paredes,Mahesh K. B. Parmar,Andrew N. Phillips,Cavan S. Reilly,Shweta Sharma,Robin L. Dewar,Marc Teitelbaum,Deborah Wentworth,Huyen Cao,Paul Klekotka,Abdel Babiker,Annetine C. Gelijns,Virginia L. Kan,Virginia L. Kan,Mark N. Polizzotto,Mark N. Polizzotto,B. Taylor Thompson,H. Clifford Lane,James D. Neaton +48 more
TL;DR: In this paper, the effect of neutralizing monoclonal antibody (YL-CoV555) on patients with Coronavirus disease 2019 (Covid-19) was investigated.
Journal ArticleDOI
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
Thomas P. Lodise,Susan L. Rosenkranz,Matthew Finnemeyer,Scott R. Evans,Matthew Sims,Marcus J. Zervos,C. Buddy Creech,Pratish Patel,Michael C. Keefer,Paul F. Riska,Fernanda P. Silveira,Marc H. Scheetz,Marc H. Scheetz,Richard G. Wunderink,Martin A. Rodriguez,John Schrank,Susan C Bleasdale,Sara Schultz,Michelle A. Barron,Ann Stapleton,Dannah Wray,Henry F. Chambers,Vance G. Fowler,Thomas L. Holland +23 more
TL;DR: Higher vancomycin exposures did not confer a lower TF risk but were associated with more AKI, and dosing should be guided by the AUC and day-2 AUCs should be ≤515.